IFM will be eligible for potential milestone payments in aggregate value of up to $835 million, giving Novartis full rights to its STING antagonist program
/PRNewswire/ IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate.
/PRNewswire/ IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate.